Conbercept
- Generic Name
- Conbercept
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1227158-72-6
- Unique Ingredient Identifier
- 1P05PW62F3
- Background
Conbercept has been investigated for the basic science of Age-related Macular Degeneration.
- Indication
用于治疗湿性年龄相关性黄斑变性(AMD)。
- Associated Conditions
- -
- Associated Therapies
- -
Conbercept in Choroidal Neovascularization Secondary to Uveitis
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Chongqing Medical University
- Target Recruit Count
- 40
- Registration Number
- NCT02934841
Intravitreal Conbercept for Idiopathic Choroidal Neovascularization
- First Posted Date
- 2016-08-05
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Jiao Mingfei
- Target Recruit Count
- 50
- Registration Number
- NCT02857517
- Locations
- 🇨🇳
Tianjin Medical University Eye Hospital, Tianjin, Tianjin, China
Initial Versus Delayed PDT Combination With Conbercept in PCV
- Conditions
- Interventions
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2019-07-19
- Lead Sponsor
- The Eye Hospital of Wenzhou Medical University
- Target Recruit Count
- 80
- Registration Number
- NCT02821520
- Locations
- 🇨🇳
Sir Run Run Shaw Hospital, affiliated with the Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳The Eye Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
🇨🇳The first affiliated hospital of Shanghai Jiaotong University, Shanghai, Shanghai, China
Conbercept Injection in Treatment of Severe Proliferative Diabetic Retinopathy
- Conditions
- Interventions
- First Posted Date
- 2016-06-28
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 112
- Registration Number
- NCT02816710
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Xiaodong Sun
- Target Recruit Count
- 141
- Registration Number
- NCT02802657
- Locations
- 🇨🇳
Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China
🇨🇳Eye & Ent Hospital of Fudan University, Shanghai, China
🇨🇳Shanghai Zhongshan Hospital, Shanghai, China
Head to Head Study of Anti-VEGF Treatment.
- Conditions
- Interventions
- First Posted Date
- 2015-10-16
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 12
- Registration Number
- NCT02577107
- Locations
- 🇨🇳
Novartis Investigative Site, Chengdu, Sichuan, China
Safety and Efficacy Study of Conbercept in Diabetic Macular Edema (DME) (Sailing)
- Conditions
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2016-01-06
- Lead Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Target Recruit Count
- 248
- Registration Number
- NCT02194634
- Locations
- 🇨🇳
Beijing Tongren hospital affiliated to Capital Medical University, Beijing, Beijing, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Southwest Hospital, Chongqing, Chongqing, China
An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)
- Conditions
- Interventions
- First Posted Date
- 2014-03-28
- Last Posted Date
- 2014-07-22
- Lead Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02098720
- Locations
- 🇨🇳
Zhongshan Ophthalmic Center,Sun yat-sen University, Guangzhou city, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.